全球药企加速布局NLRP3靶点,抗炎新药军备竞赛全面展开

DoNews
Jan 29

礼来以12亿美元溢价62%收购NLRP3抑制剂Biotech Ventyx Biosciences,推动该靶点进入产业竞争新阶段。Ventyx核心管线VTX3232为可穿透血脑屏障的口服NLRP3抑制剂,2025年10月公布的II期临床数据显示:单药治疗首周即降低超敏C反应蛋白(hsCRP)约80%,效果持续至第12周,使多数患者hsCRP维持在心血管风险阈值2 mg/L以下;虽未显示减重效应,但...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10